argenx SE filings document the regulatory record of a foreign private issuer commercializing antibody-based medicines for severe autoimmune diseases. Form 6-K reports furnish press releases, investor presentations, financial results, FDA label updates for VYVGART and VYVGART Hytrulo, and clinical data presentations for programs in myasthenia gravis, CIDP, multifocal motor neuropathy, and related neuromuscular disorders.
The filings also cover annual-report materials filed with Dutch and U.S. regulators, incorporation by reference into Form S-8 registration statements, annual general meeting notices and results, board appointments, remuneration and annual-account votes, and other governance matters. These disclosures provide the formal record for argenx's product sales, pipeline development, capital-market reporting, risk factors, and foreign-issuer status.
argenx SE reports that the U.S. FDA has approved a label expansion for its therapies VYVGART and VYVGART Hytrulo to treat all adult patients with generalized myasthenia gravis (gMG), regardless of serotype.
The decision is based on the Phase 3 ADAPT SERON study in 119 anti-acetylcholine receptor antibody–negative patients, where VYVGART produced rapid, significant and sustained symptom improvements and was well tolerated. The label now explicitly covers anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive and triple seronegative adults, addressing a historically underserved 20% of the gMG population.
argenx reported a very strong first quarter of 2026, driven by rapid growth of VYVGART. Product net sales reached $1.3 billion, up from $790 million a year earlier, representing 63% year-over-year growth. Total operating income was $1.3 billion, while operating profit rose to $394 million, compared with $139 million in 2025, reflecting margin expansion despite higher research, development and commercial spending.
Profit for the period more than doubled to $366 million from $169 million, with basic earnings of $5.90 per share versus $2.78 a year earlier. Cash, cash equivalents and current financial assets totaled $4.9 billion as of March 31, 2026, providing substantial financial flexibility.
argenx highlighted continued global uptake of VYVGART in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, along with an active late-stage pipeline. Key upcoming milestones include an FDA decision on seronegative gMG by May 10, 2026, multiple Phase 3 and Phase 2 readouts between 2026 and 2027, and advancement of empasiprubart and other immunology candidates under its “Vision 2030” strategy.
argenx announced leadership changes and shareholder voting results from its Annual General Meeting. The Board of Directors appointed Karen Massey as Chief Executive Officer, succeeding co-founder Tim Van Hauwermeiren, who becomes Chairperson of the Board as a non-executive director.
Massey joined argenx in March 2023 as Chief Operating Officer and has been central to execution and long-term growth strategy, according to the Board. At the General Meeting, 90.9% of the company’s share capital was represented and all agenda items received the required majority of votes in favor.
argenx announced leadership changes and shareholder voting results from its Annual General Meeting. The Board of Directors appointed Karen Massey as Chief Executive Officer, succeeding co-founder Tim Van Hauwermeiren, who becomes Chairperson of the Board as a non-executive director.
Massey joined argenx in March 2023 as Chief Operating Officer and has been central to execution and long-term growth strategy, according to the Board. At the General Meeting, 90.9% of the company’s share capital was represented and all agenda items received the required majority of votes in favor.
FMR LLC filed an amendment to Schedule 13G reporting beneficial ownership of 5,409,597.24 shares of common stock of ARGENX SE, representing 8.7% of the class. The filing lists sole dispositive power for 5,409,597.24 shares and notes that one or more other persons may have rights to dividends or sale proceeds. The filing identifies CUSIP N0610Q109 and cites an accompanying 13d-1(k) agreement in Exhibit 99. The amendment is signed under a power of attorney on behalf of FMR LLC and Abigail P. Johnson.
FMR LLC filed an amendment to Schedule 13G reporting beneficial ownership of 5,409,597.24 shares of common stock of ARGENX SE, representing 8.7% of the class. The filing lists sole dispositive power for 5,409,597.24 shares and notes that one or more other persons may have rights to dividends or sale proceeds. The filing identifies CUSIP N0610Q109 and cites an accompanying 13d-1(k) agreement in Exhibit 99. The amendment is signed under a power of attorney on behalf of FMR LLC and Abigail P. Johnson.
argenx filed a Form 6-K to furnish a press release highlighting new neuromuscular data being presented at the 2026 American Academy of Neurology meeting in Chicago. The company describes new results for VYVGART (IV and Hytrulo) in myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP), including treatment-naïve CIDP patients.
The update also features data for adimanebart in congenital myasthenic syndromes and broader neuromuscular pipeline progress, such as Phase 3 programs evaluating empasiprubart in CIDP. argenx outlines Phase 3 study designs in ocular MG and seronegative generalized MG, the ongoing ADAPT Jr pediatric trial, and reiterates that VYVGART and VYVGART Hytrulo are already approved for certain MG and CIDP indications in specified regions.
argenx SE is convening its Annual General Meeting of shareholders on May 6, 2026 at 13:00 CET at the Hilton Amsterdam Schiphol in the Netherlands. Shareholders and others with meeting rights are invited to attend in person or via proxy and e-voting.
The agenda includes discussion and adoption of the 2025 annual accounts, an advisory vote on the 2025 remuneration report, discharge of directors for 2025 duties, and authorization of the Board to issue shares and to limit or exclude pre-emptive rights. The company also proposes that Jim Daly retire as non-executive director and Chair of the Commercialization Committee effective May 6, 2026, with succession options under review. Meeting materials and convocation details are available on the argenx website and through the company on request.
argenx filed its Form 20-F annual report for the year ended December 31, 2025, outlining its global autoimmune-focused biopharma business. The company’s main commercial product, VYVGART (intravenous) and its subcutaneous versions, including VYVGART HYTRULO and VYVDURA, are approved in multiple regions for generalized myasthenia gravis, with additional approvals for immune thrombocytopenia in Japan and chronic inflammatory demyelinating polyneuropathy in several major markets.
argenx prepares consolidated financial statements under IFRS in U.S. dollars and reports that as of December 31, 2025, 61,883,306 ordinary shares were outstanding, including those represented by ADSs on Nasdaq. The report emphasizes extensive forward-looking statements and detailed risk factors covering market acceptance, intense competition from large pharmaceutical companies, pricing and reimbursement pressures, biosimilar threats, regulatory uncertainties, clinical trial risk, manufacturing and supply-chain dependence on third parties, and evolving healthcare and government pricing laws in the U.S., EU and other jurisdictions.
argenx filed its 2025 Annual Report with the Dutch regulator and furnished it to U.S. investors. The report shows rapid growth around VYVGART, which treated about 19,000 patients in 2025 and surpassed $1 billion in quarterly net sales for the first time in the third quarter.
Full-year product net sales were $4.2 billion, with $1.4 billion invested in research and development and headcount expanding to 1,863 employees as of December 31, 2025. The company’s Vision 2030 targets treating 50,000 patients, securing 10 labeled indications and advancing at least five pipeline candidates into Phase 3.
argenx highlights 10 ongoing registrational clinical trials across efgartigimod, empasiprubart and adimanebart, multiple new molecules entering Phase 1, and broad global approvals of VYVGART in gMG, CIDP and ITP. A CEO transition is planned in 2026, with COO Karen Massey slated to succeed Tim Van Hauwermeiren, who is expected to become Non-Executive Chairperson, subject to shareholder approval. The outlook flags key catalysts through 2027, including Phase 3 readouts in myositis, ITP, MMN and Sjögren’s disease, and an FDA decision on seronegative gMG expected on May 10, 2026.
argenx SE furnished an update highlighting upcoming scientific presentations at the 2026 American Academy of Neurology Annual Meeting. The company will showcase data for its marketed FcRn blocker VYVGART (IV and subcutaneous Hytrulo) and pipeline antibodies empasiprubart and adimanebart across several neuromuscular diseases.
Planned presentations cover generalized and ocular myasthenia gravis, including Phase 3 ADAPT OCULUS data in ocular MG, ADAPT SERON in patients without detectable AChR antibodies, and ADAPT Jr in adolescents with gMG, plus long‑term safety and real‑world experience. In CIDP, argenx will present ADHERE trial analyses, biomarker work using neurofilament light chain, real‑world treatment transition insights, and Phase 3 designs for empasiprubart. Additional Phase 1b ARGX‑119 data in DOK7 congenital myasthenic syndromes aim to support proof of concept.
argenx reported a transformational 2025, driven by its VYVGART franchise. Full-year global product net sales reached $4.2 billion, up about 90% from 2024, lifting total operating income to $4.25 billion. This delivered $1.05 billion in operating profit, marking the company’s first year of operating profitability.
Net profit for 2025 was $1.29 billion, with basic earnings of $21.08 per share, up from $13.92. Fourth-quarter product net sales were $1.29 billion, and argenx treated roughly 19,000 patients globally with VYVGART while advancing multiple Phase 3 programs and label expansions in myasthenia gravis, CIDP, and other autoimmune diseases.
argenx reported a transformational 2025, driven by its VYVGART franchise. Full-year global product net sales reached $4.2 billion, up about 90% from 2024, lifting total operating income to $4.25 billion. This delivered $1.05 billion in operating profit, marking the company’s first year of operating profitability.
Net profit for 2025 was $1.29 billion, with basic earnings of $21.08 per share, up from $13.92. Fourth-quarter product net sales were $1.29 billion, and argenx treated roughly 19,000 patients globally with VYVGART while advancing multiple Phase 3 programs and label expansions in myasthenia gravis, CIDP, and other autoimmune diseases.